Lantern Pharma Inc. · NASDAQ:LTRN
Lantern Pharma — Q1 2021 Earnings Presentation
17 slides from Lantern Pharma's earnings presentation, May 3, 2021
Slide 1: First Quarter 2021 Operating & Financial Results Conference Call
First Quarter 2021 Operating & Financial Results Conference Call May 3, 2021 https://ir.lanternpharma.com/ 4:30 PM Eastern
Slide 2: Forward-Looking Statements
LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, stateme
Slide 3: Key Topics
KEY TOPICS 1. Business Overview & Background Panna Sharma, CEO 2. Financial Results & Highlights First Quarter 2021 David Margrave, CFO Operating & Financial 3. Business Updates Results Conference Call Panna Sharma, CEO 4. Milestones May 3, 2021 Panna Sharma, CEO 4:30 PM Eastern 5. Q&A Session 3
Slide 4: Lantern leverages A.I. to rescue and develop cancer therapies
Lantern leverages A.I. to rescue and develop cancer therapies and has the potential to transform the cost, risk and timeline of drug development Failed or Abandoned Drug Assets Responders Non-Responders RADR® & New Drug Development • Big data (genomic, clinical, response) • Patient stratification ba
Slide 5: Lantern's Unique and Rapidly Developing Pipeline
Lantern’s Unique and Rapidly Developing Pipeline Indication Program R&D Preclinical Phase I Phase II Phase III Prostate Cancer LP-100 Successfully partnered & out-licensed (Irofulven) Outlicensed to Allarity Non-Small Cell Lung Cancer Targeting non-smokers with LP-300 (Focused on Non-Smokers) NSCLC
Slide 6: Key Milestones Attained During 1Q'21
Key Milestones Attained During 1Q’21 RADR® A.I. platform surpassed 4.0 billion datapoints Strengthened IP portfolio with filing of over 10 patent applications Launched R&D collaboration with Actuate Therapeutics leveraging RADR® Initiated preclinical development of LP-284 in highly sensitive hematol
Slide 7: Peer-Reviewed Publications That Further Validate RADR A.I. Platform and LP-184
Peer-Reviewed Publications That Further Validate RADR® A.I. Platform and LP-184 7
Slide 8: Summary Results of Operations
Summary Results of Operations Three Months Ended March 31, (Unaudited) 2021 2020 Operating expenses: General and administrative 1,173,258 340,172 Research and development 1,279,037 137,104 Total operating expenses 2,452,295 477,276 NET LOSS $ (2,452,295) $ (477,276) Net loss per common share, $ (0.2
Slide 9: Balance Sheet Highlights & Shares Outstanding
Balance Sheet Highlights & Shares Outstanding 3/31/2021 12/31/2020 (Unaudited) Cash $ 81,373,725 $ 19,229,232 Prepaid Expenses & Other Current Assets $1,110,770 $1,007,690 Total Assets $ 82,504,659 $ 20,359,634 Total Liabilities $ 773,033 $ 660,839 Total Stockholders’ Equity $ 81,731,626 $ 19,698,79
Slide 10: Entering "The Golden Age of A.I."
Entering “The Golden Age of A.I.” 10 Mega-Trends Setting The Stage for A.I. Led Transformation in Drug Development & Medicine ✦ Large-scale, relevant and readily available data-sets ✦ Methods, technologies and algorithms that are massively scalable ✦ Computing, storage and transmission continue expo
Slide 11: The RADR Platform Enables...
The RADR® Platform Enables... ➢ Rapid identification of potential compounds to Data Points Powering RADR® rescue and develop Scientific Value + ➢ Improved and more nuanced understanding of responder groups, and non-responder groups based on biological networks ➢ Feedback for potential mechanisms to
Slide 12: RADR Platform Key Features & Architecture
RADR® Platform Key Features & Architecture 85%+ RADR® rapidly identifies genetic & 1 Blinded biomarker signatures for precision prediction success oncology drug development, 27,000+ clinical response prediction and Cancer patient CDx (companion diagnostic) clinical histories enablement. 150+ Drug-tu
Slide 13: Growth in Data Drives Growth in Capabilities
Growth in Data Drives Growth in Capabilities 16.7x growth Over Last 12 Months (May 2020 to May 2021) (Datapoints Expressed in Millions) 8,000 • Complete transcriptome data 4,600 • RNA gene expression data • Drug sensitivity data • DNA copy number and mutation data • Clinical stage of tumor/cancer •
Slide 14: Updated Clinical Development Plans Submitted to FDA for LP-300 Phase 2 Trial
Updated Clinical Development Plans Submitted to FDA for LP-300 Phase 2 Trial For Non-smokers With NSCLC Investigational LP-300 in combination with chemo doublet - carboplatin and pemetrexed. Product Development Phase II Phase Relapsed Advanced Primary Adenocarcinoma of the Lung in Never Smoker (Chem
Slide 15: Equity-Based Collaboration with Actuate Therapeutics that Leverages RADR
Equity-Based Collaboration with Actuate Therapeutics that Leverages RADR® ● Develop predictive model of sensitivity and a potential signature of biomarkers to identify response patients for 9-ING-41. Actuate Therapeutics, Inc. is a private ● 9-ING-41 is a widely researched GSK-3β inhibitor. clinical
Slide 16: Key Value Building Objectives
Key Value Building Objectives Foundational Year Multiple Streams of Value Creation Advance Platform Launch Multiple Precision Trials Prepare Trial Launches Leverage Platform for Pharma Partners Prioritize Additional Compounds Secure Additional Compounds 2021 2022 ● Planned launch of Ph. 2 clinical t
Slide 17: Q & A
Q&A LTRN Operating & Financial Results Call May 3, 2021 17